Sirion launches trial

Sirion Therapeutics has begun enrolment for a Phase II trial of the compound fenretinide, as a treatment for geographic atrophy in patients with age-related macular degeneration.

Related Videos
© 2023 MJH Life Sciences

All rights reserved.